Teladoc Health, Inc.·4

Mar 5, 4:08 PM ET

Turitz Andrew 4

4 · Teladoc Health, Inc. · Filed Mar 5, 2024

Insider Transaction Report

Form 4
Period: 2024-03-01
Turitz Andrew
SVP - Business Development
Transactions
  • Sale

    Common Stock

    2024-03-01$15.06/sh475$7,15425,193 total
  • Exercise/Conversion

    Common Stock

    2024-03-01+4,22629,419 total
  • Exercise/Conversion

    Common Stock

    2024-03-01+43729,856 total
  • Exercise/Conversion

    Common Stock

    2024-03-01+86730,723 total
  • Exercise/Conversion

    Common Stock

    2024-03-01+1,34832,071 total
  • Exercise/Conversion

    Common Stock

    2024-03-01+12,40044,471 total
  • Exercise/Conversion

    Common Stock

    2024-03-01+1,14845,619 total
  • Sale

    Common Stock

    2024-03-04$14.52/sh6,190$89,85439,429 total
  • Award

    Performance Stock Units

    2024-03-01+12,67912,679 total
    Common Stock (12,679 underlying)
  • Exercise/Conversion

    Performance Stock Units

    2024-03-014,2268,453 total
    Common Stock (4,226 underlying)
  • Exercise/Conversion

    Performance Stock Units

    2024-03-014370 total
    Common Stock (437 underlying)
  • Exercise/Conversion

    Performance Stock Units

    2024-03-018670 total
    Common Stock (867 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2024-03-011,3485,392 total
    Common Stock (1,348 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2024-03-0112,40024,802 total
    Common Stock (12,400 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2024-03-011,1480 total
    Common Stock (1,148 underlying)
Footnotes (13)
  • [F1]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on November 27, 2023.
  • [F10]On March 2, 2022, the reporting person earned 2,602 performance stock units, vesting in three substantially equal annual installments beginning on March 2, 2022.
  • [F11]On March 1, 2022, the reporting person was granted 16,170 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter.
  • [F12]On March 3, 2023, the reporting person was granted 37,202 restricted stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter.
  • [F13]On March 2, 2021, the reporting person was granted 3,442 restricted stock units, vesting in three substantially equal annual installments beginning on the first anniversary of the grant date.
  • [F2]Performance stock units convert to shares of TDOC common stock on a one-for-one basis
  • [F3]Restricted stock units convert to shares of TDOC common stock on a one-for-one basis.
  • [F4]Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance stock unit and restricted stock unit awards.
  • [F5]Each performance stock unit represents a contingent right to receive one share of TDOC common stock.
  • [F6]Performance award amount determined based on metrics in respect of the issuer's 2023 financial results.
  • [F7]The performance stock units vest as to one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter.
  • [F8]On March 1, 2024, the reporting person earned 12,679 performance stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter.
  • [F9]On March 2, 2023, the reporting person earned 874 performance stock units, vesting in two substantially equal annual installments beginning on March 2, 2023.

Documents

1 file
  • 4
    wk-form4_1709672884.xmlPrimary

    FORM 4